Baird raised the firm’s price target on Astrana Health (ASTH) to $86 from $67 and keeps an Outperform rating on the shares. The firm said the company’s largest acquisition to date, Prospect Health, adds incredible firepower to the company’s already-attractive long-term full-risk conversion story.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: